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ABSTRACT: The present work deals with the development of cocrystal of
ambrisentan (AMT) to improve its biopharmaceutical profile. Full interaction
maps (FIM) of AMT were explored to find out the potential sites for hydrogen
bonding and prediction of supramolecular synthons. This information was further
applied to the screening of amino acids as prospective coformers for
cocrystallization of AMT. Mechanochemical reactions have resulted in two
cocrystals with L-aspartic acid and glycylglycine (dipeptide). The crystal structural
analysis revealed that the hydrogen-bonding pattern in the developed cocrystals
corroborated well with the predicted supramolecular synthons. The developed
cocrystals showed a remarkable improvement in solubility, intrinsic dissolution
rate, and in vivo systemic absorption as compared to the parent drug.
Complementarily, Hirshfeld surface maps together with crystal features established
a good structural−performance correlation of the developed cocrystals. Thus, the
systematic cocrystallization driven by structural informatics tools is valuable in the
development of novel solid forms with improved biopharmaceutical attributes.
1. INTRODUCTION
A major hurdle faced by the pharmaceutical industry in drug
development is poor water solubility, which in turn impedes
the bioavailability of new drug substances.1 Most of these
drugs belong to BCS II and IV classes, highlighting the
challenging task before pharmaceutical scientists.2 Therefore,
there is a need to screen the potential solid-state form of a drug
candidate with optimized physicochemical parameters for
better bioavailability.3,4 The crystal engineering approach
offers promising results in tailoring the biopharmaceutical
properties of drugs.5,6 Cocrystallization is driven by supra-
molecular interaction among complementary functionalities
that can be rationalized by synthons in the design of
multicomponent solid forms.7−9 Pharmaceutical cocrystals
have emerged as a viable route to optimize physicochemical
(solubility, dissolution, stability),10,11 pharmacokinetic (bio-
availability, permeability),12,13 and mechanical (flowability,
compressibility, tabletability)14,15 properties of challenging
drug molecules. Additionally, the regulatory framework by
the US-FDA considering a cocrystal as a new solid form of
active pharmaceutical ingredients will further pull the interests
of generic manufacturers toward the development of
cocrystals.16
The prerequisite for the design of cocrystals is the proper
understanding of supramolecular synthons or molecular
recognition sites for the selection of suitable coformers that
are amenable to building molecular interaction. However,
screening of a large array of coformers requires several
cocrystallization experimental trials, which is a time-consuming
process often resulting in few hits.17 Therefore, the selection of
potential coformers at a very early stage of cocrystal design
would limit the experimental attempts, time, as well as cost.
The Cambridge Structural Database (CSD) offers structural
informatics tools for cocrystal design, prediction of cocrystal
outcomes, and screening of potential coformers.18 The various
structural informatics tools employed are CSD intermolecular
interaction search (ConQuest),19 hydrogen bond motif
search,20 hydrogen bonding propensity (HBP) prediction,21
and molecular complementarity.22 Besides, the full interaction
map (FIM)23 tool maps the entire molecule, reflecting the
likelihood of supramolecular synthons by probing the func-
tional groups, and is useful in the prediction of molecular
crystal structures.
Ambrisentan (AMT) is an endothelin type A (ETA) receptor
blocker and is approved for the treatment of pulmonary arterial
hypertension (PAH).24 The poor water solubility (0.06 mg/
mL) of AMT qualifies the drug to be categorized as BCS class
II.25 Form I of AMT is the only solid form which is approved
for marketing under the brand name Letairis.26 Our research
group has explored this drug by developing its metastable solid
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form (form II) and extensively studied its thermodynamic and
surface anisotropic behavior.27,28 Besides, a solid dispersion of
ambrisentan has also been reported29 using a natural carrier to
improve its bioavailability. However, amorphization of the
resulting mixture together with an increase in bulk size further
limits the translation to finished drug product. Therefore, the
development of the multicomponent form based on the crystal
engineering approach is a better alternative to improve the
bioavailability of the selected drug. The availability of the
pyrimidine ring and free carboxylic group in AMT further pulls
our interest in developing cocrystals with complementary
functional groups. Our recent study showed the propensity of
AMT for cocrystallization with syringic acid (phenolic acid
coformer).30 Motivated from the recent work, research was
initiated to systematically explore other potential coformers
using crystal engineering and structural informatics tools.31
Current literature shows that the full interaction map (FIM)
tool of CSD has been effectively used in the cocrystallization of
drug molecules.32−34 The present attempt is focused on the
application of FIM to identify functionalities capable of
forming facile supramolecular synthons with recognition sites
in the drug molecule. This information was further applied to
the screening of amino acids as prospective coformers for
cocrystallization of AMT. The developed cocrystals were
characterized using various analytical techniques. Besides, the
structural−performance relationship has been derived from
their physicochemical and biopharmaceutical properties.
2. EXPERIMENTAL SECTION
2.1. Materials. Ambrisentan (AMT) as form I was gifted by Dr
Reddy’s Laboratories, Hyderabad, India. Glycylglycine (GG, 99%
purity) and L-aspartic acid (LAA, 99% purity) were procured from
Himedia Laboratories Pvt. Ltd. (Mumbai, India) and used without
any purification. All other chemicals and solvents were of analytical
grade.
2.2. Preparation of the Cocrystals. The liquid-assisted grinding
approach was used in the preparation of cocrystals in the presence of a
catalytic amount of solvent. A stoichiometric amount of AMT (378.4
mg, 1 mmol) was ground separately with GG (132.1 mg; 1 mmol)
and LAA (133.1 mg; 1 mmol) using an agate mortar and pestle with
the addition of a few drops of ethanol, and ground for 30 min. The
resulting solid mass was labeled AGG and ALAA, stored in a
desiccator overnight, and characterized by various analytical tools.
2.3. Characterization Techniques. Differential scanning calo-
rimetry (DSC) analyses of the samples were carried out using DSC
Q20 (TA Instruments, New Castle, DE, USA) which was calibrated
for temperature and heat flow accuracy using indium (mp 156.6 °C
and ΔH of 25.45 J g−1). Solid samples (4−6 mg) were placed in
sealed nonhermetic aluminum pans and were scanned from 20 to 300
°C at 10 °C/min scanning rate under a dry nitrogen atmosphere (flow
rate 50 mL/min). The data were analyzed using TA Instruments
universal analysis 2000 software.
Powder X-ray diffraction (PXRD) of powder samples was recorded
on the X’Pert PRO diffractometer system (PANalytical, Almelo,
Netherlands) with a Cu Kα radiation (1.54060 Å). The tube voltage
and current were set at 45 kV and 40 mA, respectively. Diffraction
pattern was measured by a continuous scan between 5° and 50° in 2θ
with a step size of 0.017° and a step time of 25 s/step. Data was
refined using X’Pert HighScore Plus software.
Fourier transform infrared (FTIR) spectra were recorded using
Spectrum II (PerkinElmer, Waltham, MA, USA) in transmittance
mode. Each spectrum was scanned in the range of 4000−400 cm−1
with a resolution of 4 cm−1, and a minimum of 16 scans was collected
and averaged. Data were analyzed using Spectrum software.
13C-solid-state nuclear magnetic resonance (SSNMR) spectra were
recorded on Jeol Resonance 400 MHz spectrometer (Jeol, Peabody,
Massachusetts, USA). SSNMR measurements were carried out on a 4
mm double resonance CP-MAS probe at 10 kHz spinning rate with a
cross-polarization contact time of 3.5 ms and delay of 5 s using Delta
NMR software.
2.4. Crystal Structure Determination from PXRD. BIOVIA
Material Studio software (ver. 7.0) was used for the determination of
the crystal structure of prepared cocrystal using the reflex plus
module. The overall prediction process was carried out in four steps:
indexing, Pawley fitting, structure solution, and Rietveld refinement.
The optimized structure was further solved using Monte Carlo/
simulated annealing procedure. Finally, Rietveld refinement of the
structure solution was processed to obtain a final structure.35
2.5. Hirshfeld Surface Analysis. Crystal Explorer 3.0 program
was used to carry out Hirshfeld surface analysis (HSA) and generate
fingerprint plots. The plots were used to describe various
intermolecular interactions present in crystal structures of AGG,
ALAA, and AMT. Crystallographic information files (CIFs) were used
as input for the analysis. Directions and strengths of intermolecular
interactions within the crystals were mapped onto the Hirshfeld
surfaces using the descriptor “dnorm”, which is a ratio encompassing
the distances of any surface point to the nearby interior (di) and
exterior (de) atoms and the van der Waals radii of the atoms.28
2.6. Physicochemical Evaluation. Apparent solubility was
measured in 0.1 N HCl (pH 1.2) by suspending excess solid
(cocrystal and parent drug) in 5 mL of media which is pre-
equilibrated at 37 °C. The slurry obtained was shaken in a water bath
shaker for 24 h. Samples were filtered through a 0.22 μm membrane
filter and drug concentration was determined after appropriate
dilution using the reported HPLC method.27 The concentration of
the sample was calculated from the calibration plot of the drug. Each
experiment was repeated three times and average values were
calculated.
Intrinsic dissolution study was carried out using a compressed disc
of constant surface area (0.5 cm2) of powder samples (cocrystals and
parent drug) on USP Dissolution apparatus (DS8000; LabIndia
Analytical, Thane (West), Maharashtra, India). The compact disc was
prepared using 100 mg powder sample with a hydraulic press at 55
MPa for 5 min and attached to a rotating disc holder. An intrinsic
dissolution experiment was performed in a dissolution medium
containing 500 mL of 0.1 N HCl (pH 1.2) preheated to 37.5 °C. The
speed of the rotating disc holder was maintained at 150 rpm. Aliquots
(5 mL) were withdrawn at a specified time interval, and concentration
was determined from the calibration plot of AMT. The intrinsic
dissolution rate (IDR) was calculated from linear regression analysis
of the amount of drug dissolved per unit surface area of the compact
disc for over 60 min.
2.7. In Vivo Pharmacokinetic Study. The animal study protocol
was approved by the Institutional Animal Ethics Committee, Panjab
University, Chandigarh, India (PU/IAES/S/14/77) following the
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA, 2015) guidelines for a laboratory
animal. Male Wistar rats (∼250 g) housed under standard laboratory
conditions (25 ± 2 °C and 55 ± 5% relative humidity) with free
access to standard diet and water. Animals were divided into three
groups (AMT, AGG, and ALAA); each group consisted of four
animals (n = 5). A single dose of all the samples equivalent to 2.5 mg
kg−1 body weight was suspended in 0.5% (w/v) sodium
carboxymethylcellulose (CMC) and administered by oral gavage.
Serial blood samples were collected from the retro-orbital venous
plexus of the rats at 0 (predose), 0.5, 2, 4, 8, 12, 18, and 24 h into
heparinized plastic tubes. The blood samples were then centrifuged at
10,000 rpm (1180g) for 10 min. The plasma was separated and
treated with acetonitrile for protein precipitation. The treated plasma
samples were stored at −20 °C until drug analysis was carried out by
the reported HPLC method.27 Pharmacokinetic parameters such as
Cmax, AUC0−t, and relative bioavailability were calculated by using
noncompartmental analysis employing Kinetica 5.0 (Thermo
Scientific, Waltham, MA, USA).
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3. RESULTS AND DISCUSSION
3.1. Analysis of Full Interaction Maps (FIM) of
Ambrisentan. FIM study was conducted to identify the
active functional groups in the AMT molecule that are capable
of potential interactions with another molecule. These
interaction maps displayed the hydrogen bond acceptor and
hydrogen bond donor sites around AMT that will help in the
prediction of facile supramolecular synthons. These identified
synthons between the drug molecule and surrounding sites will
subsequently guide in the selection of suitable coformers for
the cocrystallization. Figure 1a clearly shows the hot spot
interaction regions (dark red contours, acceptor probe maps;
and dark blue contours, donor probe maps), as well as some
more transparent interaction regions (opaque red contours)
around major fragments of the AMT. The interaction maps
with dark contours (red/blue) suggest that these function-
alities have high propensities for synthon formation, while
transparent regions have lower propensities. Visual analysis of
FIM of AMT shows that the hydroxyl of free carboxylic acid is
surrounded by red hot spots indicating good sites for
interaction with an acceptor group. Similarly, the carbonyl of
free carboxylic acid, as well as the pyrimidine ring, is
surrounded by blue hot spots suggesting interaction sites for
a donor group. Interestingly, these interaction maps are very
well correlated with the experimental crystal structure of
polymorphic form I reported in the literature.36 Form I showed
a linear arrangement of AMT molecules and is sustained by
hydrogen bonding interaction between OHacid and pyrimidine
nitrogen. However, in the reported crystal structures, the C
Oacid group was not observed to satisfied the hydrogen bond
donor preference maps which are seen in the FIM. The
unsatisfied donor maps can be exploited by designing a
cocrystal of AMT by selecting a suitable hydrogen bond
donating coformer. Besides, many weak red contours have
appeared around phenyl rings, although this region is free from
any potential hydrogen bond donor groups. However, some
weakly activated C−H donors of phenyl hydrogen atoms can
also participate in the interaction with suitable hydrogen bond
accepting coformer.
3.2. Synthon Identification and Coformer Selection.
FIM study provides the preferred sites (Figure 1b) that have
high propensities to engage in hydrogen bond interaction with
complementary functional groups in AMT. Based upon the
observation of FIMs, the most suitable functional groups that
may satisfy both donor and acceptor maps could be −OH,
−NH2, and −COOH. These functional groups may have the
propensity to interact with complementary functionality in
AMT and can be divided into six synthon networks (Figure
1c). Owing to the close presence of red and blue interaction
maps around free carboxylic acid in AMT, it is speculative that
both single and two-point interactions could be possible.
Therefore, synthon types I and II have been identified showing
two-point interaction between acid−acid and acid−pyrimidine.
Besides, four different synthons (Types III, IV, V, and VI) have
been identified, highlighting single point interaction with the
preferred sites. Taking into account FIMs analysis and
identified synthons, the complementary functionalities such
as free carboxylic acid and amino groups may contribute to the
development of cocrystal with AMT through one of the
identifiable synthons.
Amino acids seem to be a valuable choice as coformer
because of their structural features (possessing both acidic and
amide groups), good water solubility, low cost, and belonging
to GRAS category. Amino acids have been extensively reported
in the literature for the development of pharmaceutical
cocrystals.37 Therefore, nine different amino acids and one
dipeptide (Table 1, Supporting Information) have been
selected to drive the screening process for cocrystallization.
The inclusion of the dipeptide (Glycylglycine) in the cocrystal
screening was not a straightforward idea, but to compare the
Figure 1. Full interaction map (FIM) around ambrisentan (form I). Regions of likely acceptor are shown in red, donors in blue, and hydrophobic
groups in orange (a); Potential fragments in ambrisentan molecule for intermolecular interaction (D and A denotes likely hydrogen bond donor
and acceptor, respectively, in another molecule) (b); Prediction of synthons (Types I−VI) based on FIM (c).
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outcomes with glycine only. The screening was conducted
using a mechanochemical approach, preferably liquid assisted
grinding (described in experimental section 2.2), and the
ground product was characterized by various analytical tools.
3.3. Characterization of Cocrystals. PXRD is an important
tool for the identification of new crystalline phases with
distinct diffraction patterns.38 PXRD patterns (Figure 2) of
AGG reveal new signature peaks at 2θ values 16.6° and 17.6°,
while the diffraction peaks of AMT and GG, respectively, at
8.9° and 34.7° disappeared. In the case of ALAA (Figure 3),
new peaks appeared at 2θ values 11.1°, 16.5°, 17.5°, and 31.2°,
while the prominent peak of AMT at 8.9° disappeared.
Besides, some peaks of AMT at 24.3° and 22.9° were shifted,
respectively, to 25.6° and 22.6° in ALAA. The emergence of
distinct diffraction patterns of AGG and ALAA confirms the
formation of the cocrystal. DSC curves provide good evidence
for the phase purity of cocrystal.39 DSC profile of AMT shows
melting endotherm at 181 °C, while selected coformers, viz.,
GG and LAA shows endothermic events corresponding to
their melting point at 241 and 239 °C, respectively (existence
of adjacent endoderm is ascribed to polymorphic trans-
formation). The liquid-assisted ground product of AGG and
ALAA revealed a single melting endotherm at 220 and 215 °C,
respectively (SI Figures 1 and 2). It is quite clear that the
melting point of both ground products appeared in between
the parent molecules as sharp and single peak indicating the
existence of a homogeneous crystalline phase without any
impurity of drug and coformers.
The molecular interaction between the cocrystal forming
components has been explored by studying their vibrational
spectra. The FTIR spectrum (SI, Figure 3) of AGG shows
shifting in the CO stretching band of AMT from 1752 to
1745 cm−1. Similarly, carbonyl stretching band of GG at 1660
cm−1 has shifted to 1662 cm−1 in AGG. Moreover, the OH
wagging in AMT and GG at 981 and 964 cm−1 has also shifted
to 998 cm−1. This infers some form of interaction between
carbonyl and OHacid functionalities between drug and
coformer. Additionally, the bending modes of NH2 in GG
show shifting from 1575 to 1545 cm−1 indicating the
involvement of free amino group also in hydrogen bonding
in the resultant cocrystal. In the case of ALAA cocrystal,
carbonyl stretching of AMT shifts from 1752 to 1745 cm−1,
while the bending vibration of CN is shifted from 1559 to
1542 cm−1 (SI, Figure 4). Besides, OH bending of LAA shifted
from 1419 to 1425 cm−1 in ALAA. The changes in the
signature vibrational bands in ALAA are indicative of a possible
interaction between complementary functionality, i.e., carbonyl
of LAA and Narom of AMT.
13C SSNMR offers valuable information on hydrogen
bonding and is used as an important tool in understanding
structural changes in multicomponent system.40 13C SSNMR
spectrum of AGG showed some perturbance at the acidic C8
signal of AMT with a subtle shifting from 171 to 170 ppm,
while a signal corresponding to acidic C1′(GG) was shifted
from 174 to 173 ppm (SI, Figure 5). It is worth noting that the
signal at 169 ppm corresponding to C1 (AMT) remain intact
in AGG, which infers that the environment of Narom was
unaltered in the cocrystal. The above changes observed in the
13C SSNMR spectra are indicative of hydrogen bonding
between corresponding acid functionalities among drug and
coformer. Similarly, 13C SSNMR spectrum of ALAA (SI,
Figure 6) showed a shift in signals of LAA from 176 ppm
(C4′) and 175 ppm (C1′) to 175 and 174 ppm, respectively.
Besides, subtle shifting was observed for the signal correspond-
ing to C1 of AMT from 169 to 168 ppm in the resultant
cocrystal. The above observation suggests the involvement of
Table 1. Crystallographic Parameters of Developed
Cocrystals (AGG and ALAA)
parameters AGG ALAA
Molecular formula C26H30N4O7 C26H29N3O8
Molecular weight 510.54 511.52
Crystal system Monoclinic Orthorhombic









2θ range 5−50° 5−50°
CCDC deposition number 1868627 1868620
Figure 2. Overlay of PXRD patterns of AMT, GG, and AGG
cocrystal.
Figure 3. Overlay of PXRD patterns of AMT, LAA, and ALAA
cocrystal.
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pyrimidine nitrogen (Narom adjacent to C1) in hydrogen
bonding with OH of the carboxylic group (either C4′ or C1′).
Further, to understand which OHacid is involved in the
supramolecular interaction, the pattern of carbon signals was
closely examined. In cocrystal, C1′ signal noticeably merged
toward the signal of C8 of AMT, while C4′ appeared relatively
sharp; therefore, it is anticipated that OH of C4′ may be
involved in the hydrogen bonding above. Additionally, a signal
corresponding to C8 in AMT exhibits downfield shifting from
171 to 170 ppm with the bifurcation of the peak of equal
intensity. This leads to the assumption that carboxylic acid
(C8) may undergo dimer formation with another molecule.
Further, it is reported41 that there is a higher chemical shift
(180 ppm) after conversion of carboxylic acid to carboxylate
form. It is interesting to mention that no signal at this region
was noticed in the spectra of both cocrystals (AGG and
ALAA), thus negating the assumption of salt formation.
3.4. Crystal Structure Determination from PXRD. The
attempts to develop a single crystal of two developed cocrystals
failed due to the incongruent solubility of drug and coformers
in the crystallizing solvents. Therefore, the crystal structure
data of cocrystals were solved from their unique PXRD
patterns. A good correlation exists between simulated and
experimental powder diffraction patterns (SI, Figures 7 and 8).
The crystallographic information on these cocrystals is
summarized in Table 1. AGG crystal data reveals that the
carbonyl of the carboxylic group in AMT interacts with OHacid
groups of GG as well as OHacid of another AMT molecule,
leading to bifurcated CO···HO hydrogen bonds (synthons
III) with a graph set (3) chain. This feature is very well
correlated with the FIMs of AMT where dark blue contours
were found near carbonyl of the acidic group and remain
unsatisfied in the crystal structure of pure AMT (form I).
Therefore, the success of the AGG cocrystal could be driven by
synthons III acting as a primary structural unit. However, the
bifurcate bonding of the carbonyl group is ascribed to the
presence of lone pairs on the oxygen atom. Additionally, two
inversion-related GG molecules form a dimer with a (16) ring
motif through a NH···O network (synthons IV) between
terminal secondary amine NH and carbonyl of carboxylic acid
(Figure 4a). The GG dimer acting as a bridge to further
propagate the hydrogen-bonded network with other AMT
molecules thus acted as auxiliary interaction. It is quite evident
that the crystal structure of AGG is sustained by two types of
the supramolecular network via types III and IV synthons. The
packing structure of AGG showing a 3D supramolecular
assembly of AMT and GG molecules via strong hydrogen
bonding (Figure 4b).
The crystal structure of ALAA shows that the carboxylic OH
of LAA forms bifurcated hydrogen bondsone with
pyrimidine nitrogen of AMT via OH···Narom interaction
(synthon V) with a graph set (4) and another with an ether
linkage of AMT via OH···O network. The existence of
synthons V very well agrees with the calculated interaction
maps where pyrimidine ring, as well as oxygen atom (ether
linkage), were surrounded by dark blue contours (hydrogen
bond donor maps). The availability of a free OHacid group of
the coformer within the contours may effectively satisfy the
interaction preferences leading to the bifurcation of the
hydrogen bond. Besides, the availability of terminal carboxylic
functional groups in both AMT and LAA follow a self-
recognition pattern through the carboxylic acid dimeric
interaction (synthon I) forming an (8) ring motif (Figure
5a). The cocrystallization of ALAA is driven by synthons V as a
primary structural unit, while synthons I are assumed to be an
auxiliary interaction. It is interesting to mention that synthons
V also exist in the crystal structure of AMT resulting in a
dimeric interaction.36 However, the formation of cocrystals has
disrupted this homomeric AMT interaction, and a new
heteromeric (drug−coformer) interaction is propagated by
the bifurcated synthon network. The packing structure of
ALAA shows a 3D supramolecular assembly of AMT and LAA
molecules via strong hydrogen bonding (Figure 5b). It is worth
mentioning that the synthon network observed in both
cocrystals corroborated well with either one or more of the
supramolecular synthons predicted by the FIM approach.
3.5. Structure−Performance Relationship of Devel-
oped Cocrystals. 3.5.1. Apparent Solubility and Structural
Features Correlation. Apparent solubility of cocrystals of
AMT were measured in 0.1 N HCl at 37 °C for 24 h. AGG
(0.65 ± 0.005 mg/mL) and ALAA (0.17 ± 0.006 mg/mL)
show significant (P > 0.001) improvement in aqueous
solubility as compared to pure AMT (0.07 ± 0.02 mg/mL).
The correlation of physicochemical properties of a cocrystal
with crystal structure features is difficult. Therefore, commonly
used factors in these studies are cocrystal composition,
cocrystal melting point, coformer water solubility, and
molecular features.42,43 The aqueous solubility experiment
revealed that the developed cocrystal has improved solubility
compared to pure AMT. By carefully examining the crystal
Figure 4. (a) Intermolecular interaction between AMT and GG
molecules in cocrystal via supramolecular synthon network
[bifurcated CO···OHacid (AMT)/ CO···OHacid (GG) and NH···O
dimer]; (b) Packing diagram of the 3D supramolecular network
formed by AMT and GG molecules in cocrystal via strong hydrogen
bonds. Hydrogen bonds to carbon atoms are hidden to improve
clarity. Expanded and hanging hydrogen-bonded contacts are
represented in dotted green and cyan color, respectively.
Figure 5. (a) Intermolecular interaction between AMT and LAA
molecules in cocrystal via supramolecular synthon network
[bifurcated OH···Narom/OH···O and COOH···COOH dimer]; (b)
Packing diagram of the 3D supramolecular network formed by AMT
and LAA molecules in cocrystal via strong hydrogen bonds. Hydrogen
bonds to carbon atoms are hidden to improve clarity. Expanded and
hanging hydrogen-bonded contacts are represented in dotted green
and cyan color, respectively.
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structure of the parent drug, it showed that there is a linear
chain of homomeric synthon between carboxylic acid and
pyrimidine nitrogen (OH···Narom) (SI, Figure 9). However, in
AGG cocrystal, this primary synthon is absent, which may
result in the improvement of its aqueous solubility. Conversely,
ALAA cocrystal comprises OH···Narom heterosynthon, similar
to the parent drug, but bifurcated with an additional OH···O
network, which may be ascribed to its higher solubility than
the parent drug. It is also mentioned that the coformer
solubility also influences the solubility of the corresponding
cocrystal.44,45 It is found that the aqueous solubility of GG is
relatively higher than the LAA, which may be responsible for
imparting higher solubility to AGG as compared to ALAA.
Overall, the modified synthon network together with hydro-
philic coformers may play a role in improving the aqueous
solubility of both the cocrystals over the parent drug.
3.5.2. Intrinsic Dissolution Study and Hirshfeld Surface
Analysis Correlation. Figure 6 depicts the intrinsic dissolution
release profile of cocrystal of AMT in 0.1 N HCl (pH 1.2)
dissolution medium at 37 °C. Among developed cocrystals,
AGG showed higher IDR (0.165 ± 0.001 mg/cm2/min) than
ALAA (0.097 ± 0.001 mg/cm2/min). The IDR of both
cocrystals was found to be significantly higher (P > 0.001) than
the pure AMT (0.061 ± 0.001 mg/cm2/min). Up to 2.7-fold
and 1.6-fold improvement in IDR of AGG and ALAA,
respectively, was observed as compared to the parent drug.
The significant improvement in dissolution rate in cocrystals is
attributed to their better solubility. However, the dissolution is
both a kinetic and surface phenomenon. Therefore, the factors
responsible for solubility improvement may not be directly
applicable to IDR. Hence, the surface molecular interaction in
the developed cocrystals was mapped by studying their
molecular Hirshfeld surface analysis (HSA) using Crystal
Explorer. A plot of di versus de is a 2D fingerprint plots, which
recognizes the existence of different types of intermolecular
interactions and examine the local packing. 2D fingerprint
plots of AMT and cocrystals were studied and found that
among all the contacts, H···H, C···H, N···H, and O···H were
predominant. It is quite evident (Figure 7) that the polar
interaction O···H is dominant in AGG (20.4%) over ALAA
(16.2%) compared to AMT (14.2%), while N···H was found to
be dominant in pure AMT (8.2%) as compared to developed
cocrystals. Further, the percent contribution of nonpolar
interaction, especially C···H in both cocrystals (ranges from
15−18%), was less than that in AMT (20.3%). Besides, in both
cocrystals as well as AMT, the major contribution arises from
the longer contacts H···H (53−57%). The above observation
gives the correlation between polar surface contacts and IDR
of developed cocrystals. The quantitative order of percent
polar contacts in different solid forms AGG > ALAA > AMT
was found to be analogous to their dissolution release profile. It
is anticipated that the presence of hydrophilic coformers in the
developed cocrystal contributes to the dominance of polar
surface molecular environment, which are otherwise absent in
the parent drug. On exposure to the aqueous medium, water-
Figure 6. Intrinsic dissolution release profile of cocrystals (AGG and
ALAA) and parent drug.
Figure 7. Left: 2D fingerprint plots derived from total Hirshfeld surface area for cocrystals and parent drug. Spikes labeled 1−4 represent the H···H,
N···H, O···H, and C···H interaction respectively. Right: Relative percent contribution of the intermolecular interactions to the Hirshfeld surface for
cocrystals and parent drug.
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soluble coformers in cocrystals easily develop newer contacts
with the solvent which facilitates solubilization of the coformer
molecules together with breaking of the crystal lattice. The
remaining AMT molecules may form a transient amorphous
aggregate which quickly solubilizes in the solution resulting in
an enhanced dissolution rate.46 The dissociation of coformer
from the cocrystal was quite evident from the PXRD study of
IDR disc scrap after the experiment, which resembles the
diffraction pattern of the parent drug (SI, Figures 10 and 11).
3.6. In Vivo Pharmacokinetic Study. Pharmacokinetic
profiles of AMT and its cocrystals were determined by
noncompartmental methods. Various pharmacokinetic param-
eters were determined using Kinetica software and are shown
in Table 2. The developed cocrystals demonstrated superior
bioavailability owing to an increase in the extent of absorption
(Cmax and AUC) and are depicted in Figure 8. Nearly 2-fold
and 1.1-fold improvement in AUC were observed in AGG and
ALAA, respectively, as compared to a parent drug suspension.
Percent Cmax of developed cocrystals was in the range of 21−
170% higher than the parent drug. This significant improve-
ment can be attributed to the faster absorption of drug
molecules in systemic circulation, which is ascribed to their
high dissolution rate. Furthermore, improved pharmacokinetic
profiles of developed cocrystals are found in good correlation
with their in vitro dissolution study. Thus, the augmentation in
the oral bioavailability of cocrystals is the interplay of their
surface as well as structural features generated from drug−
coformer interactions.
4. CONCLUSIONS
The present study highlights the successful attempt in the
development of new cocrystals of AMT with amino acid (L-
aspartic acid) and dipeptide (glycylglycine). The observed
intermolecular interaction in cocrystals recognized the
predicted supramolecular synthons through full interaction
map approach. The developed cocrystals (AGG and ALAA)
showed higher solubility and intrinsic dissolution rate as
compared to the parent drug. The marked improvement in
physicochemical properties of cocrystals was eloquently
correlated with their structural features as well as the surface
molecular environment using Hirshfeld surface analysis. This
correlation suggested that the existence of supramolecular
synthons and dominance of the polar molecular surface in
cocrystals are responsible for their improved in vitro perform-
ance as compared to pure AMT. The advantage of better
physicochemical properties in cocrystals translated into the
overall augmentation of oral bioavailability in a pharmacoki-
netic study. It is important to mention that the FIM tool
cannot mitigate the failure of cocrystallization despite having
complementary functionality among coformers. That is the
reason many selected amino acids (except L-aspartic acid and
dipeptide, glycylglycine) failed to give the cocrystal with drug
molecule. It is believed that molecular size/shape comple-
mentarity and strength of cohesive and adhesive interaction
may also be taken into consideration during the screening
experiment. Besides, the ability of glycylglycine to generate
cocrystal shows that deliberate efforts can be made to consider
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